PCVX vs PTGX
Vaxcyte, Inc. vs Protagonist Therapeutics, Inc. — AI-powered side-by-side comparison
PCVX
Vaxcyte, Inc.
67
Buy
VS
PTGX
Protagonist Therapeutics, Inc.
64
Buy
| Metric | PCVX | PTGX |
|---|
| AI Score |
67
|
64
|
| Price |
$59.60
|
$151.99
|
| P/E Ratio |
-7.75×
|
121.74×
|
| ROE |
-28.5%
|
-21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
0.0%
|
99.9%
|
| Debt / Equity |
0.04×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
65.6
|
68.1
|
| Beta |
1.21
|
1.794
|
| Expected Upside |
+4.2%
|
—
|
AI Committee View
Current Innellis committee reasoning for PCVX versus PTGX.
PCVX leads by 3 points.
PCVX scores 67/100 (Buy) versus PTGX at 64/100 (Buy).
PCVX Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -37.6% -- cheap may mean cheap for a reason — Value
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
PTGX Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 34.8% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 115.4 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 34.8% YoY -- genuine top-line momentum — Growth
- EPS growing 46.0% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 115.4 is expensive by classic value standards — Value
- Price-to-book of 8.9x prices in significant intangible value — Value
- Weekly RSI at 84 -- overbought on the larger timeframe too — Technical